Braveheart Bio, Inc. BRVE
Set alert
21.13 USD +0.09 +0.40%
As of Nov 3, 1:20 PM ET
20.24 Day range 21.51
18.58 52-week range 30.00
- YTD
- -29.11%
- 1 year
- -29.11%
- Open
- 20.94
- Prev close
- 21.04
- Mkt cap
- 1.91B
- Vol
- 62.33K
- Avg vol
- 477.30K
- EPS
- -6.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 20.24
- High
- 21.51
- Forward P/E
- -10.57
- Beta
- 0.00
- Short ratio
- 8.11
- Inst. own
- 28.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 8, 2026
- 50-d avg
- 23.52
- 200-d avg
- 24.23
- 1y target
- 45.25
Key statistics
- Market cap
- 1.89B
- Enterprise value
- 1.85B
- Trailing P/E
- 0.00
- Forward P/E
- -10.57
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -6.08
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 122.83M
- Total debt
- 575.00K
- Return on equity
- 0.00%
- Shares outstanding
- 90.04M
- Short % of float
- 0.00%
- 50-day average
- 23.52
- 200-day average
- 24.23
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 45.25 +114.2% upside
Now 21.13
- Target (low)
- 40.00
- Target (mean)
- 45.25
- Target (high)
- 48.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 8, 2026
Expected Dec 8, 2026. Consensus EPS estimate 0.00.
Financials — quick view
BRVE Revenue — quarterly 0
BRVE Net income — quarterly -14.99M
BRVE EPS — quarterly -2.51
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 8, 2026 | Sep 30, 2026 | -0.438 | — | — | — |
| Sep 8, 2026 | Jun 30, 2026 | 2.69 | -2.51 | -5.20 | -193.31% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
About Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- braveheart.bio
News
- Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The American Heart Association Scientific Sessions, November 6-9; Will Also Host Webinar
- Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
- Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
- Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product
- Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target
- Braveheart Bio (NASDAQ:BRVE) Stock Falls 7.3% – Here’s What Happened
- Braveheart Bio to Participate in Stifel Cardiometabolic Forum
- Braveheart Bio Q2 EPS $(2.51)
- Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
- Braveheart Bio to Participate in Cantor Global Healthcare Conference
Your note
Sign in to keep a note on BRVE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHIMOVITS EREZ | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 6, 2026 | 0 |
| JIANGSU HENGRUI PHARMACEUTICALS CO. LTD. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 6, 2026 | 7,420,090 |
| LUBNER DAVID CHARLES | Director | Purchase | Aug 6, 2026 | 55,555 |
| MURDOCH TRAVIS | Chief Executive Officer | Purchase | Aug 6, 2026 | 8,333,640 |
| RICKEY JAMES PAUL | Chief Financial Officer | Purchase | Aug 6, 2026 | 703,575 |
| VIEHBACHER CHRISTOPHER | Director | Purchase | Aug 6, 2026 | 759,857 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Leonard Rickey Investment Advisors P.L.L.C. | 0.04% | 36,109 | 759.73K | Sep 29, 2026 |
| SBI Securities Co., Ltd. | 0.00% | 10 | 210 | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 2.52% | 2,273,151 | 47.83M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.87% | 779,600 | 16.40M | Aug 30, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 0.67% | 600,000 | 12.62M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.60% | 537,444 | 11.31M | Aug 30, 2026 |
| MFS SERIES TRUST I-MFS New Discovery Fund | 0.38% | 345,984 | 7.28M | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.30% | 265,638 | 5.59M | Aug 30, 2026 |